Updates are available Correction dated 2023-03-22
Click to view Correction: https://doi.org/10.1038/s41598-023-31836-w
-
Authors
Fisher, Cody R.
Salmons, Harold I.
Mandrekar, Jay
Greenwood-Quaintance, Kerryl E.
Abdel, Matthew P.
Patel, Robin
-
Funding
Funding for this research was provided by:
Mayo Clinical Graduate School of Biomedical Sciences, PhD Training Grant in Basic Immunology ((NIH R25 GM055252 24)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR056647)
- License Information
-
More Information
Article History
Received: 22 December 2021
Accepted: 13 September 2022
First Online: 27 September 2022
Change Date: 22 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-023-31836-w
Competing interests
: RP reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. RP is a consultant to Next Gen Diagnostics, PathoQuest, PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, CARB-X, HealthTrackRx and Netflix. Mayo Clinic and RP have a relationship with Adaptive Phage Therapeutics. In addition, RP has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. RP receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. MPA receives royalties from Stryker on certain hip and knee products and serve on the AAOS Board of Directors. All other authors report no conflicts of interest.
